153 related articles for article (PubMed ID: 16596010)
1. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ishii Y; Shoji N; Kimura Y; Ohyashiki K
Intern Med; 2006; 45(5):339-40. PubMed ID: 16596010
[No Abstract] [Full Text] [Related]
2. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.
Sanchez-Gonzalez B; Pascual-Ramirez JC; Fernandez-Abellan P; Belinchon-Romero I; Rivas C; Vegara-Aguilera G
Blood; 2003 Mar; 101(6):2446. PubMed ID: 12609964
[No Abstract] [Full Text] [Related]
3. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Dann EJ; Fineman R; Rowe JM
J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
[No Abstract] [Full Text] [Related]
4. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
Swords R
Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
[No Abstract] [Full Text] [Related]
5. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
6. Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Suzuki R; Kobayashi C; Sakai A; Fukushima H; Tagawa M; Satomi K; Nanmoku T; Sumazaki R; Fukushima T
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e368-71. PubMed ID: 25929609
[TBL] [Abstract][Full Text] [Related]
7. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?
Bassan R
Leuk Lymphoma; 2011 Jul; 52(7):1164-5. PubMed ID: 21612380
[No Abstract] [Full Text] [Related]
8. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
[TBL] [Abstract][Full Text] [Related]
9. Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia.
Thomas D
Lancet Oncol; 2012 Sep; 13(9):860-2. PubMed ID: 22935232
[No Abstract] [Full Text] [Related]
10. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Brandwein J
Drugs; 2007; 67(17):2655. PubMed ID: 18034600
[No Abstract] [Full Text] [Related]
11. Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
De Vita S; De Matteis S; Laurenti L; Chiusolo P; Sorà F; Piccirillo N; Reddiconto G; Fiorini A; Leone G; Sica S
Ann Oncol; 2006 Apr; 17(4):720-1. PubMed ID: 16263757
[No Abstract] [Full Text] [Related]
12. Post-fracture excessive callus formation in a child on imatinib therapy.
Ramzan M; Verma R; Chopra YR; Yadav SP
Pediatr Blood Cancer; 2013 Dec; 60(12):2087-8. PubMed ID: 24038762
[No Abstract] [Full Text] [Related]
13. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Wassmann B
Drugs; 2007; 67(17):2656. PubMed ID: 18034598
[No Abstract] [Full Text] [Related]
14. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Cross SA; Lyseng-Williamson KA
Drugs; 2007; 67(17):2645-54. PubMed ID: 18034597
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Takeuchi M; Koseki M; Uryu H
Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
[No Abstract] [Full Text] [Related]
16. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
[No Abstract] [Full Text] [Related]
17. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
Matsue K; Matsuo K; Fujiwara H; Iwama K; Hayama BY; Kimura S; Yamakura M; Takeuch M
Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163
[No Abstract] [Full Text] [Related]
18. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ottmann OG; Wassmann B
Hematology Am Soc Hematol Educ Program; 2005; ():118-22. PubMed ID: 16304368
[TBL] [Abstract][Full Text] [Related]
19. Reversible cardiotoxicity with tyrosine kinase inhibitors.
Francis J; Ahluwalia MS; Wetzler M; Wang E; Paplham P; Smiley S; McCarthy PL; Cohen IL; Spangenthal E; Battiwalla M
Clin Adv Hematol Oncol; 2010 Feb; 8(2):128-32. PubMed ID: 20386534
[No Abstract] [Full Text] [Related]
20. Imatinib mesylate-induced pseudoporphyria in two children.
Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
